Literature DB >> 8947528

The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines.

D W Miller1, M Fontain, C Kolar, T Lawson.   

Abstract

The presence of P-glycoprotein (P-gp) and multiple drug resistance-associated protein (MRP) was examined in four human pancreatic adenocarcinoma cell lines (PANC-1, BxPC-3, AsPC-1, and Capan-1). Cellular accumulation of rhodamine 123 and [3H]vincristine were used to determine functional activity of P-gp and MRP, respectively. None of the cells showed any evidence of P-gp in the rhodamine 123 cellular accumulation assays. In contrast, PANC-1, BxPC-3 and AsPC-1 did display an increased accumulation of [3H]vincristine following treatment with either cyclosporin A or verapamil. Western blot analysis confirmed the expression of MRP, and little, if any, measurable P-gp in the cell lysates. These studies suggest that intrinsic drug resistance in pancreatic duct cancer may be due in part to the presence of MRP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947528     DOI: 10.1016/0304-3835(96)04384-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

Review 1.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers.

Authors:  D W Miller; E V Batrakova; A V Kabanov
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

3.  Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor.

Authors:  J V Aukunuru; G Sunkara; N Bandi; W B Thoreson; U B Kompella
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

4.  Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine.

Authors:  Elaine Tseng; Amrita Kamath; Marilyn E Morris
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 5.  Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Authors:  Jing Li; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-03-03       Impact factor: 4.009

6.  Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.

Authors:  B Liu; E Staren; T Iwamura; H Appert; J Howard
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

7.  Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.

Authors:  Ngoc H On; Fang Chen; Martha Hinton; Donald W Miller
Journal:  Pharm Res       Date:  2011-05-20       Impact factor: 4.200

Review 8.  Pancreatic cancer stem cells: fact or fiction?

Authors:  Vikash J Bhagwandin; Jerry W Shay
Journal:  Biochim Biophys Acta       Date:  2009-02-21

9.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

10.  Cytotoxicity screening of Bangladeshi medicinal plant extracts on pancreatic cancer cells.

Authors:  Sherine George; Siddharth V Bhalerao; Erich A Lidstone; Irfan S Ahmad; Atiya Abbasi; Brian T Cunningham; Kenneth L Watkin
Journal:  BMC Complement Altern Med       Date:  2010-09-17       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.